Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02144155 · ClinicalTrials.gov registry record · NA
Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia
A NA study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT02144155: Clinical Trial NA study, sponsored by University of California, San Diego.
NCT02144155 is a NA study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02144155, a NA study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The Objective of this study is to investigate the long-term efficacy of intranasal oxytocin in improvement of symptoms in patients with schizophrenia who have residual symptoms dispute being on adequate treatment with antipsychotic medication.
Primary Outcome
The three subscales of the PANSS include the Positive scale (7 items), the Negative scale (7 items), and the General Psychopathology scale (16 items). The total PANSS score is the sum of all 30 items of which each item is scored on a 1-7 rating system (7 indicating the worst symptoms). The items on the PANSS focus on symptoms that are common in patients with psychotic disorders and include hallucinations, delusions and disorganization as well as mood disturbances.
Interventions
- DRUG Placebo
- DRUG Oxytocin: 24IU - 168 IU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-12 |
| Phase | NA |
Why NCT02144155 stopped before completion
NCT02144155 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02144155 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02144155 about?
NCT02144155 is a clinical study titled "Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia". The Objective of this study is to investigate the long-term efficacy of intranasal oxytocin in improvement of symptoms in patients with schizophrenia who have residual symptoms dispute being on adequate treatment with antipsychotic medication.
What is the current status of trial NCT02144155?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2012-03. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02144155?
The interventions under investigation include: Placebo (DRUG), Oxytocin: 24IU - 168 IU (DRUG).
Who is sponsoring clinical trial NCT02144155?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02144155's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia